Raymond James Financial Inc. Invests $15.99 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

Raymond James Financial Inc. acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 102,061 shares of the company's stock, valued at approximately $15,989,000. Raymond James Financial Inc. owned 0.35% of Krystal Biotech at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. US Bancorp DE lifted its position in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares during the period. Crossmark Global Holdings Inc. lifted its position in Krystal Biotech by 5.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after purchasing an additional 121 shares during the period. Perigon Wealth Management LLC lifted its position in Krystal Biotech by 1.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock valued at $1,200,000 after purchasing an additional 123 shares during the period. KBC Group NV lifted its position in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company's stock valued at $117,000 after purchasing an additional 132 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Krystal Biotech by 3.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company's stock valued at $840,000 after purchasing an additional 153 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of research reports. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of "Buy" and a consensus price target of $220.00.

Krystal Biotech Stock Performance

Shares of KRYS stock traded down $1.46 on Friday, reaching $187.15. 328,246 shares of the company were exchanged, compared to its average volume of 283,881. The company has a market cap of $5.39 billion, a price-to-earnings ratio of 62.59 and a beta of 0.87. The business has a 50-day moving average price of $166.67 and a 200 day moving average price of $173.74. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.30 earnings per share. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).